Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Alaunos Therapeutics (NASDAQ: TCRT): A Pivot From TCR-T Cancer Therapy to Obesity

Alaunos now describes itself as a developer of oral therapeutics targeting obesity as a potential alternative to injectable GLP-1 drugs. Its lead candidate, ALN1003, has generated positive preclinical proof-of-concept data, with the company reporting metabolic improvements, including weight loss and improved insulin sensitivity, in …

Nitish Kishor | 10 September 2026

SOHM Inc (OTC: SHMN): A Generic Pharma Business With a Gene-Editing Storyline

SOHM develops, manufactures, markets and distributes generic and private-label pharmaceutical products in the United States, spanning analgesics, antibiotics, anti-cold and anti-inflammatory medicines, along with cosmeceutical and nutraceutical lines. More recently, the company has promoted a gene-editing effort branded ABBIE and a collaboration with Coastar …

Nitish Kishor | 10 September 2026

Ultragenyx Pharmaceutical (NASDAQ: RARE): A GSDIa Approval Amid an Angelman Setback

Ultragenyx develops treatments for rare and ultra-rare genetic diseases, spanning approved products such as Crysvita, Dojolvi and Mepsevii alongside a deep gene-therapy and RNA pipeline. In August 2026, the company disclosed U.S. FDA approval of GENGLYCOS, its gene therapy for Glycogen Storage Disease Type …

Nitish Kishor | 10 September 2026

Agios Pharmaceuticals (NASDAQ: AGIO): A Pending FDA Decision on Sickle Cell Disease

Agios is built around PYRUKYND (mitapivat), an oral pyruvate kinase activator, following the company's earlier exit from oncology. Its most consequential near-term event is regulatory: the FDA granted priority review to a supplemental application for mitapivat in sickle cell disease, with a decision date …

Nitish Kishor | 10 September 2026

Axim Biotechnologies (OTC: AXIM): A Diagnostics Developer's Transparency Gap

Axim develops diagnostic healthcare solutions for ophthalmological conditions, including point-of-care tests for dry eye disease and allergic conjunctivitis, and it has operated a center for custom biomarker and biopharmaceutical research. The most consequential recent corporate event, however, is regulatory housekeeping rather than product news: …

Nitish Kishor | 10 September 2026

Enlivex Ltd (NASDAQ: ENLV): Pairing Allocetra With a Prediction-Markets Treasury

Based in Tel Aviv, Enlivex develops Allocetra, an allogeneic, off-the-shelf cell-based immunotherapy designed to rebalance the immune system. Its lead indication is age-related symptomatic primary knee osteoarthritis in older patients. In July 2026 the company said Allocetra received U.S. Food and Drug Administration Regenerative …

Nitish Kishor | 10 September 2026

Creative Medical Technology Holdings (NASDAQ: CELZ): ADAPT Trial Enrollment Completed

Based in Phoenix, Arizona, Creative Medical Technology develops cell-based and immunotherapy products across regenerative medicine, immunology and urology. Its lead clinical asset is CELZ-201, also known as olastrocel, an allogeneic cell therapy being studied for chronic lower back pain caused by degenerative disc disease. …

Nitish Kishor | 10 September 2026

SQZ Biotechnologies (OTC: SQZB): From Cell-Therapy Pioneer to Deregistered Shell

SQZ Biotechnologies was a Massachusetts-based, clinical-stage company developing cell-engineering therapies using its proprietary "Cell Squeeze" platform, which momentarily deforms a cell's membrane to deliver antigens and other cargo, with lead programs in immuno-oncology. The company's most consequential recent development is procedural: SEC records show …

Nitish Kishor | 10 September 2026

GelStat Corp (OTC: GSAC): Stepping Back From Regulation A Reporting

GelStat Corporation, incorporated in Delaware and based in Miami, is classified under pharmaceutical preparations and traces its corporate history back to an entity formerly named Developed Technology Resource Inc before adopting the GelStat name in 2003. Rather than filing standard 10-Ks and 10-Qs, GelStat …

Nitish Kishor | 10 September 2026

Revelation Biosciences (NASDAQ: REVB): Gemini's Path Toward the TITAN Trial

Revelation Biosciences is developing Gemini, a phosphorylated hexaacyl disaccharide (PHAD)-based immunomodulator, with its lead program targeting acute kidney injury (AKI), a common and serious complication with few effective preventive therapies. The most recent verified milestone came on August 19, 2026, when Revelation said it …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…